Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 14/20 | 0.68 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.68 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31169607 | 1.00 | DDB1 (0.68) | DDB1CRBNGPR119MAP4K4CKS1B | |
| SCHEMBL27036800 | 0.87 | DDB1 (0.58) | DDB1CRBNGPR119 | |
| SCHEMBL20595415 | 0.85 | DDB1 (0.74) | DDB1CRBNGPR119 | |
| SCHEMBL21903077 | 0.85 | DDB1 (0.74) | DDB1CRBNGPR119 | |
| SCHEMBL29744797 | 0.85 | DDB1 (0.74) | DDB1CRBNGPR119 | |
| SCHEMBL24125934 | 0.85 | DDB1 (0.58) | DDB1CRBNGPR119 | |
| SCHEMBL25074522 | 0.83 | CRBN (0.70) | DDB1CRBNGPR119MAP4K4CKS1B | |
| SCHEMBL24881041 | 0.83 | CRBN (0.70) | DDB1CRBNGPR119MAP4K4CKS1B | |
| SCHEMBL29977355 | 0.83 | CRBN (0.70) | DDB1CRBNGPR119MAP4K4CKS1B | |
| SCHEMBL29208509 | 0.83 | CRBN (0.70) | DDB1CRBNGPR119MAP4K4CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| CN-119233974-A | Indolone derivative and application thereof | 康百达（四川）生物医药科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| CN-118159532-A | Compound with BTK protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024017372-A1 | INDOLONE DERIVATIVE AND USE THEREOF | 成都百裕制药股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| WO-2023080732-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | DDB1 1245/4885CRBN 324/4885GPR119 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.